Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.
OBJECTIVE
To ascertain the incidence/clinical implications of isolated autosomal trisomies in adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry.


RESULTS
Of the 3179 cytogenetically informative AMLs diagnosed January 1997-May 2015, 246 (7.7%) had isolated trisomies. The frequency increased by age (2.4% at age 18-60 years vs. 23% at >60 years; P<.0001); the median age was 69 years. The five most common were +8 (4.0%), +13 (0.9%), +11 (0.8%), +21 (0.7%), and +4 (0.5%). Age and gender, types of AML and treatment, and complete remission and early death rates did not differ between the single trisomy and the intermediate risk (IR) groups or among cases with isolated gains of chromosomes 4, 8, 11, 13, or 21. The overall survival (OS) was similar in the single trisomy (median 1.6 years) and IR groups (1.7 years; P=.251). The OS differed among the most frequent isolated trisomies; the median OS was 2.5 years for +4, 1.9 years for +21, 1.5 years for +8, 1.1 years for +11, and 0.8 years for +13 (P=.013).


CONCLUSIONS
AML with single trisomies, with the exception of +13, should be grouped as IR.
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.|Stem Cell Center, Lund University, Lund, Sweden.
Vladimir Lj
http://orcid.org/0000-0002-1782-4423
VL
Lazarevic
Epidemiology and Registry Center in South Sweden, Skåne University Hospital, Lund, Sweden.|Medical Radiology, Department of Translational Medicine, Lund University, Lund, Sweden.
Aldana
A
Rosso
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.|Stem Cell Center, Lund University, Lund, Sweden.
Gunnar
G
Juliusson
Department of Hematology, Linköping University Hospital, Linköping, Sweden.
Petar
P
Antunovic
Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Åsa Rangert
ÅR
Derolf
Department of Medicine, Division of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Stefan
S
Deneberg
Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Lars
L
Möllgård
Department of Medicine, School of Health and Medical Sciences, Örebro University Hospital, Örebro, Sweden.
Bertil
B
Uggla
Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Lovisa
L
Wennström
Department of Radiation Sciences, Umeå University, Umeå, Sweden.
Anders
A
Wahlin
Department of Hematology, Academic Hospital, Uppsala, Sweden.
Martin
M
Höglund
Department of Hematology, Academic Hospital, Uppsala, Sweden.
Sören
S
Lehmann
Department of Clinical Genetics, University and Regional Laboratories Region Skåne, Lund, Sweden.|Division of Clinical Genetics, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Bertil
B
Johansson
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D011379:Prognosis; D012042:Registries; D012306:Risk; D016019:Survival Analysis; D013548:Sweden / Q000453:epidemiology; D014314:Trisomy; D055815:Young Adult
acute myeloid leukemia; autosomal trisomy; clinical characteristics; survival